Murine cytomegalovirus infection directs macrophage differentiation into a pro-inflammatory immune phenotype: implications for atherogenesisVLIEGEN, Inge; DUIJVESTIJN, Adrian; STASSEN, Frank et al.Microbes and infection. 2004, Vol 6, Num 12, pp 1056-1062, issn 1286-4579, 7 p.Article

Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus ReplicationDELANG, Leen; VLIEGEN, Inge; FROEYEN, Mathy et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 9, pp 4103-4113, issn 0066-4804, 11 p.Article

In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitorsDELANG, Leen; VLIEGEN, Inge; LEYSSEN, Pieter et al.Journal of hepatology. 2012, Vol 56, Num 1, pp 41-48, issn 0168-8278, 8 p.Article

Rapid identification of bacteria by real-time amplification and sequencing of the 16S rRNA geneVLIEGEN, Inge; JACOBS, Jan A; BEUKEN, Erik et al.Journal of microbiological methods. 2006, Vol 66, Num 1, pp 156-164, issn 0167-7012, 9 p.Article

Immune activation following cytomegalovims infection : More important than direct viral effects in cardiovascular disease? : CMV part IISTASSEN, Frank R; VEGA-CORDOVA, Xavier; VLIEGEN, Inge et al.Journal of clinical virology. 2006, Vol 35, Num 3, pp 349-353, issn 1386-6532, 5 p.Article

Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activationVLIEGEN, Inge; DUIJVESTIJN, Ad; GRAULS, Gert et al.Microbes and infection. 2004, Vol 6, Num 1, pp 17-24, issn 1286-4579, 8 p.Article

Debio 025, a Cydophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) InhibitorsCOELMONT, Lotte; KAPTEIN, Suzanne; PAESHUYSE, Jan et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 3, pp 967-976, issn 0066-4804, 10 p.Article

Substituted imidazopyridines as potent inhibitors of HCV replicationVLIEGEN, Inge; PAESHUYSE, Jan; OARE, David et al.Journal of hepatology. 2009, Vol 50, Num 5, pp 999-1009, issn 0168-8278, 11 p.Article

Mechanistic Characterization of GS-9190 (Tegobuvir), a Novel Nonnucleoside Inhibitor of Hepatitis C Virus NS5B PolymeraseSHIH, I-Hung; VLIEGEN, Inge; XIAOPING QI et al.Antimicrobial agents and chemotherapy. 2011, Vol 55, Num 9, pp 4196-4203, issn 0066-4804, 8 p.Article

Statins Potentiate the In Vitro Anti-Hepatitis C Virus Activity of Selective Hepatitis C Virus Inhibitors and Delay or Prevent Resistance DevelopmentDELANG, Leen; PAESHUYSE, Jan; VLIEGEN, Inge et al.Hepatology (Baltimore, Md.). 2009, Vol 50, Num 1, pp 6-16, issn 0270-9139, 11 p.Article

Mouse cytomegalovirus antigenic immune stimulation is sufficient to aggravate atherosclerosis in hypercholesterolemic miceVLIEGEN, Inge; HERNGREEN, Selma B; GRAULS, Gert E. L. M et al.Atherosclerosis. 2005, Vol 181, Num 1, pp 39-44, issn 0021-9150, 6 p.Article